The shortage of the widely-used anticoagulant apixaban in Finland has led to significant distress due to skyrocketing prices and limited access, caused by a patent dispute among pharmaceutical companies.
In Finland, the widely-used anticoagulant medication apixaban, needed by over 150,000 people, has been in short supply since the beginning of the year. This situation has arisen due to a patent dispute between pharmaceutical companies, resulting in most generic alternatives being withdrawn from the market late last year. Consequently, the only remaining option is the branded medication Eliquis, which costs over three times as much as its generics,
The shortage has led to financial strain for many patients who rely on this crucial medication for their health. One reader shared their experience of having to pay nearly 46 euros for a month’s supply, a stark contrast to the previous year's price of less than 20 euros. Many patients are expressing their frustration, highlighting the challenge of affording a medication necessary for their quality of life.
As the cost of the only remaining medication continues to rise, some patients are seeking alternatives and further consultation with their doctors to explore more affordable options. The situation highlights the broader implications of corporate disputes on public health and access to essential medications in Finland, raising concerns about medication availability and affordability moving forward.
